Evidence map›Paper›PMID 23707407›Full record

ArticleJournal of molecular biology2013

PLEIAD/SIMC1/C5orf25, a novel autolysis regulator for a skeletal-muscle-specific calpain, CAPN3, scaffolds a CAPN3 substrate, CTBP1.

Yasuko Ono, Shun-Ichiro Iemura, Stefanie M Novak, Naoko Doi, Fujiko Kitamura, Tohru Natsume, Carol C Gregorio, Hiroyuki Sorimachi

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Relaxin-2: Shaping the Proteomic Landscape of Skeletal Muscle Physiology, Glucose Trafficking, and Mitochondrial Function in Rat.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The N- and C-terminal autolytic fragments of CAPN3/p94/calpain-3 restore proteolytic activity by intermolecular complementation.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yasuko OnoCalpain Project, Department of Advanced Science for Biomolecules, Tokyo Metropolitan Institute of Medical Science (IGAKUKEN), 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan. ono-ys@igakuken.or.jp
Shun-Ichiro Iemura
Stefanie M Novak
Naoko Doi
Fujiko Kitamura
Tohru Natsume
Carol C Gregorio
Hiroyuki Sorimachi
Tokyo Metropolitan Institute of Medical Science · JPUniversity of Arizona · USNational Institute of Advanced Industrial Science and Technology · JP

Funding

Deciphering the Roles of Nebulin in Cardiac Myofibril AssemblyR01HL083146 · NHLBI · UNIVERSITY OF ARIZONA · PI GREGORIO, CAROL C · 2007 to 2011
$2.1M
Deciphering the role of the RNA-binding protein, FXR1, in cardiac muscle assemblyR01HL108625 · NHLBI · UNIVERSITY OF ARIZONA · PI GREGORIO, CAROL C · 2012 to 2015
$1.9M
Novel Protein Kinase C Isoforms in Ventricular MyocytesR01HL081386 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GREGORIO, CAROL C · 2005 to 2009
$1.6M
NHLBI NIH HHS HL083146NHLBI NIH HHS HL108625NHLBI NIH HHS R01 HL081386NHLBI NIH HHS R01 HL083146NHLBI NIH HHS R01 HL108625
6 · The paper itself

Abstract

CAPN3/p94/calpain-3 is a skeletal-muscle-specific member of the calpain protease family. Multiple muscle cell functions have been reported for CAPN3, and mutations in this protease cause limb-girdle muscular dystrophy type 2A. Little is known about the molecular mechanisms that allow CAPN3 to be so multifunctional. One hypothesis is that the very rapid and exhaustive autolytic activity of CAPN3 needs to be suppressed by dynamic molecular interactions for specific periods of time. The previously identified interaction between CAPN3 and connectin/titin, a giant molecule in muscle sarcomeres, supports this assumption; however, the regulatory mechanisms of non-sarcomere-associated CAPN3 are unknown. Here, we report that a novel CAPN3-binding protein, PLEIAD [Platform element for inhibition of autolytic degradation; originally called SIMC1/C5orf25 (SUMO-interacting motif containing protein 1/chromosome 5open reading frame 25)], suppresses the protease activity of CAPN3. Database analyses showed that PLEIAD homologs, like CAPN3 homologs, are evolutionarily conserved in vertebrates. Furthermore, we found that PLEIAD also interacts with CTBP1 (C-terminal binding protein 1), a transcriptional co-regulator, and CTBP1 is proteolyzed in COS7 cells expressing CAPN3. The identified cleavage sites in CTBP1 suggested that it undergoes functional modification upon its proteolysis by CAPN3, as well as by conventional calpains. These results indicate that PLEIAD can shift its major function from CAPN3 suppression to CAPN3-substrate recruitment, depending on the cellular context. Taken together, our data suggest that PLEIAD is a novel regulatory scaffold for CAPN3, as reflected in its name.

Indexed as

Alcohol OxidoreductasesAnimalsCalpainCarrier ProteinsChlorocebus aethiopsCOS CellsDNA-Binding ProteinsGene Expression RegulationHumansMuscle ProteinsMuscle, SkeletalProtein BindingProteolysisAlcohol OxidoreductasesCalpainCAPN3 protein, humanCarrier ProteinsC-terminal binding proteinDNA-Binding ProteinsMuscle ProteinsSIMC1 protein, humanautolysiscalpainNational Center for Biotechnology InformationNCBIscaffoldskeletal musclesubstrateyeast two-hybridYTH

Identifiers

PMID23707407
PMCPMC5576862
OpenAlexW2052341480

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.